/

Empresas

Da

No verificado

Daiichi Sankyo

Sobre qué escribimos

FarmacéuticaIndustriaMedicina - VariosOncologíaSalud

82 Comunicados de prensa

Ver todos los comunicados de prensa

22/01/2026

Oncología

Salud

Ciencia

Farmacéutica

Biotecnología

Mercado laboral

Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe

Fuente

Editor

1.00

0

19/01/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fuente

Editor

1.00

0

13/01/2026

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Industria

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Fuente

Editor

1.00

0

07/01/2026

Oncología

Salud

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

Mercado laboral

Industria

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

Fuente

Editor

1.00

0

22/12/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

Fuente

Editor

1.00

0

22/12/2025

Industria

Oncología

Salud

Higiene alimentaria

Biotecnología

Medicina - Varios

Farmacéutica

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

18/12/2025

Industria

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Fuente

Editor

1.00

0

15/12/2025

Industria

Ciencia

Farmacéutica

Oncología

Ir de compras

Biotecnología

Medicina - Varios

Salud

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fuente

Editor

1.00

0

09/12/2025

Industria

Biotecnología

Salud

Farmacéutica

Oncología

Ciencia

Ir de compras

Medicina - Varios

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

Fuente

Editor

1.00

0

08/12/2025

Biotecnología

Farmacéutica

Salud

Industria

Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0